Navigation Links
Virologists make major step towards understanding the process of HIV infection

A working group of virologists headed by Professor Hans-Georg Kräusslich at Heidelberg University Hospitals, jointly with Professor Hanswalter Zentgraf, Division of Applied Tumor Virology of the Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ), have been the first to label Human Immunodeficiency Viruses (HIV) for visual investigations without inhibiting the functional characteristics of the virus.

The labeling permits scientists to observe the behavior of the virus when it enters a host cell, during replication and when it leaves a cell. This is a major step towards understanding the process of HIV infection.

Modern imaging technologies facilitate real-time observation of virus-cell interactions. Many of these investigation methods require labeling of the object of interest, such as by introducing the genetic code of green fluorescent protein (GFP) into its genetic information. There the marker protein will be produced by the cellular machinery and appended to the desired site.

To observe the interaction of HIV with the host cell, there had also been attempts to label the virus with GFP. However, the genetic modifications impaired the formation of virus particles or their infectiousness, thus limiting the value of results obtained. A team of Heidelberg researchers of the university hospitals?Virology Section and the DKFZ have now found an area within the structure molecule of the viral capsid that tolerates the substantial extension by GFP. Although the insertion of the GFP molecule enlarges the HIV structure protein by about one half, infectious viruses continue to be generated. Using electron microscopy, Zentgraf’s team was able to show that appearance and shape of the virus particles thus created cannot be distinguished from normal HIV. By simultaneous production of GFP-extended and normal structure protein, PD Dr. Barbara Müller was able to produce, under a fluorescence microscope, clearly visible HIVs with several th ousand GFP molecules that were as infectious as HIV without GFP. This is an essential step towards a better understanding of the dynamics of HIV infection.

The task of the Deutsches Krebsforschungszentrum in Heidelberg (German Cancer Research Center, DKFZ) is to systematically investigate the mechanisms of cancer development and to identify cancer risk factors. The results of this basic research are expected to lead to new approaches in the prevention, diagnosis and treatment of cancer. The Center is financed to 90 percent by the Federal Ministry of Education and Research and to 10 percent by the State of Baden-Wuerttemberg. It is a member of the Helmholtz Association of National Research Centers (Helmholtz-Gemeinschaft Deutscher Forschungszentren e.V., HGF).


'"/>

Source:Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ)


Related biology news :

1. Jefferson Virologists Coax HIV Out of Hiding
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Researchers uncover sequence of major rice pathogen
4. Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed
5. Biochemists report discovery of structure of major piece of telomerase; implications for cancer
6. Biota makes major antiviral discovery
7. New gene scanning technology marks a major advance in disease research
8. LIAI scientists make major finding on potential smallpox treatment
9. MicroRNAs have shaped the evolution of the majority of mammalian genes
10. MIT: Oceans are a major gene swap-meet for plankton
11. U-M scientists identify major psoriasis susceptibility gene
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... ... February 17, 2017 , ... Academy of Model Aeronautics ... leading maker of unmanned aircraft systems (UAS), are launching a joint program to ... effectively, and support educational outreach efforts. , AMA and DJI will collaborate on ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... Avomeen & ... The event will be held at Avomeen Analytical Services (4840 Venture Dr., Ann ... MichBio member organization. They provide an opportunity to interact with peers, make new connections ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life Sciences ... development of liquid biopsy tests based on the ... an exclusive license agreement with its first international ... liquid biopsy test for prostate cancer, the Prostate ... . This is the first overseas appointment ...
(Date:2/16/2017)... 16, 2017   Capricor Therapeutics, Inc. ... company developing first-in-class biological therapies for cardiac and ... elected to terminate its license agreement with the ... including Cenderitide. "Our decision to return ... prioritize our efforts to advance our core cell ...
Breaking Biology Technology: